We ran a second mIHC panel to assess differences in protein levels of PD-L1, adenosine A2A receptor (A2AR), and NY-ESO-1 in CD8+ T cells and tumor cells (Figure 7A) in patients with a durable CBR versus nonresponders, before and after treatment. This evidence concerns the gene CD8A and neoplasm.